Pfizer launches early study of cancer drug atirmociclib in healthy volunteers
NCT ID NCT07215078
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study by Pfizer will give atirmociclib to 72 healthy adults to see how the drug moves through the body at different doses after a meal. Participants will receive four single doses in a random order, with blood samples taken to measure drug levels. The goal is to find the right dose for future studies, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atirmociclib (PF-07220060)
What this could lead to
If successful, this study will help determine the right dose of atirmociclib for future trials, potentially leading to a treatment for certain cancers.
What could go wrong
This is a very early Phase 1 study in healthy volunteers, not patients. It only measures drug levels and short-term safety; it cannot show whether the drug works against any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer Clinical Research Unit - New Haven
RECRUITINGNew Haven, Connecticut, 06511, United States